Type 1 interferons and myositis.
Recent studies suggest a mechanistic role for molecules induced by type 1 interferons in the pathogenesis of some forms of myositis. For dermatomyositis, evidence that these molecules injure myofibers seems especially strong. In the group of disorders known as polymyositis, the study of blood samples suggests a potential role. It is unknown what drives the sustained presence of type 1 interferon-inducible molecules in these diseases, as the type 1 interferons themselves have not been specifically detected along with their downstream biomarkers. Therapeutic development for blockade of IFNα is in progress aided by the identification of blood genomic biomarkers.
Greenberg
Steven A
SA
Department of Neurology, Division of Neuromuscular Disease, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. sagreenberg@partners.org
D015415:Biomarkers; D003882:Dermatomyositis / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000276:immunology / Q000473:pathology; D003937:Diagnosis, Differential; D005786:Gene Expression Regulation / Q000276:immunology; D006801:Humans; D007370:Interferon Type I / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000097:blood / Q000235:genetics / Q000276:immunology*; D058990:Molecular Targeted Therapy; D018482:Muscle, Skeletal / Q000098:blood supply / Q000276:immunology / Q000473:pathology; D018979:Myositis, Inclusion Body / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000276:immunology / Q000473:pathology; D009928:Organ Specificity; D017285:Polymyositis / Q000097:blood / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000097:blood; D053633:Receptor, Interferon alpha-beta / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction; D012867:Skin / Q000276:immunology / Q000473:pathology; D014158:Transcription, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D015415:Biomarkers; C507964:IFNAR1 protein, human; D007370:Interferon Type I; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D053633:Receptor, Interferon alpha-beta
Brain. 2008 May;131(Pt 5):1228-40
18420712
Ann Rheum Dis. 2008 Dec;67(12):1670-7
18272672
Lancet. 1983 Jan 15;1(8316):127-8
6129442
FEBS Lett. 1998 Mar 20;425(1):112-6
9541017
N Engl J Med. 1979 Jul 5;301(1):5-8
449915
Ann Neurol. 2005 May;57(5):664-78
15852401
EMBO J. 1998 Nov 16;17(22):6660-9
9822609
Muscle Nerve. 2003 Dec;28(6):659-82
14639580
Science. 1982 Apr 23;216(4544):429-31
6176024
Arthritis Rheum. 2009 Jul;60(7):2193-200
19565506
Ann Neurol. 2010 Jan;67(1):53-63
20186858
Eur Neurol. 2008;59(3-4):159-63
18230873
Arthritis Rheum. 2007 Nov;56(11):3784-92
17968926
Lab Invest. 1985 Jun;52(6):638-49
3892155
Ann Rheum Dis. 1970 Jan;29(1):67-72
5416101
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
12604793
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3372-7
15728381
Br J Dermatol. 2009 Feb;160(2):464-5
19077075
Arthritis Rheum. 2009 Jun;60(6):1815-24
19479879
J Neuroimmunol. 1995 Dec;63(1):9-16
8557829
Lab Invest. 1988 May;58(5):584-9
2835552
Clin Exp Immunol. 1986 Feb;63(2):450-8
2421951
Arthritis Rheum. 2007 Dec;56(12):3995-4004
18050196
J Neuropathol Exp Neurol. 1975 Jan;34(1):46-75
1117321
Hum Pathol. 1989 Mar;20(3):224-31
2470663
FEBS Lett. 1998 Dec 11;441(1):106-10
9877175
Mol Med. 2007 Jan-Feb;13(1-2):59-68
17515957
Ultrastruct Pathol. 1986;10(1):77-85
3008393
Arthritis Rheum. 1982 Apr;25(4):396-400
6176247
Neurology. 2007 Nov 20;69(21):2008-19
17928577
Autoimmunity. 2006 May;39(3):177-90
16769651
Immunity. 2000 Oct;13(4):539-48
11070172
Curr Opin Neurol. 2004 Jun;17(3):359-64
15167072
Cancer Res. 1984 Aug;44(8):3480-8
6744275
Arthritis Rheum. 1982 Apr;25(4):401-6
6176248
Arthritis Rheum. 2006 Jun;54(6):1906-16
16736505
Curr Opin Neurol. 2009 Oct;22(5):516-23
19680126